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ORIGINAL ARTICLE
Pirfenidone treatment in idiopathic pulmonary fibrosis:
nationwide Danish results
Goran Nadir Salih1*, Saher Burhan Shaker1, Helle Dall Madsen2 and
Elisabeth Bendstrup3
1Department of Respiratory Medicine, Gentofte University Hospital, Hellerup, Denmark; 2Department of
Respiratory Medicine, Odense University Hospital, Odense, Denmark; 3Department of Respiratory Diseases
and Allergy, Aarhus University Hospital, Aarhus, Denmark
Background: Pirfenidone was approved by the European Medicines Agency and introduced in most European
countries in 2011 for treatment of idiopathic pulmonary fibrosis (IPF).
Objective: To describe the national Danish experiences of pirfenidone treatment for IPF during 30 months
with respect to target population, safety, adherence to the treatment and effect analysis in a well-characterised
IPF population in a real-life setting.
Methods: Retrospective data collection from medical records of all patients in Denmark with IPF from 2011
to 2014. Data included baseline demographics, high-resolution computed tomography (HRCT), histopathology,
forced vital capacity (FVC) and 6-min walk test (6MWT). Longitudinal data on FVC, walk test, adherence to
the treatment and vital status were also collected.
Results: Pirfenidone treatment was initiated in 113 patients. Mean age was 69.698.1 years (9SD), and 71%
were male. Definite IPF diagnosis required thoracoscopic lung biopsy in 45 patients (39.8%). The remai-
ning 68 cases had a definite (64 patients) or possible usual interstitial pneumonia (four patients) pattern
on HRCT. Patients were followed for 0.133.8 months (median 9.4 months). Fifty-one patients (45.2%)
needed dose adjustment, 18 (16%) patients discontinued therapy and 13 patients (11.5%) died. The annual
mean decline in FVC was 164 ml (SE 33.2). The decline in 6MWT was 18.2 m (SE 11.2). Nausea (44.2%),
fatigue (38.9%) and skin reactions (32.7%) were frequent adverse events.
Conclusion: Patients with IPF treated with pirfenidone experienced tolerable adverse events. Patients were
maintained on treatment due to a careful follow-up and dose adjustment programme. The annual decline in
physiological parameters and mortality rate was comparable to previous randomised controlled trials.
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I
diopathic pulmonary fibrosis (IPF) is a specific
type of chronic, progressive fibrosing interstitial
pneumonia of unknown origin with a dismal prog-
nosis and a median survival of 35 years after confirmed
diagnosis (1).
Pirfenidone is the first evidence-based treatment for
IPF. Pirfenidone was approved by the European Medicines
Agency in February 2011 (2) and has been available in
Denmark since December 2011. In 2011, the Danish
Society of Respiratory Medicine recommended that treat-
ment for IPF was centralised to three tertiary interstitial
lung disease (ILD) centres and that pirfenidone treatment
was prescribed to patients with a confident diagnosis of
IPF and with mild-to-moderate physiological limitation,
that is, within the inclusion and exclusion criteria of the
CAPACITY trials (3).
Five randomised controlled trials (RCTs) have shown a
clinically meaningful effect of pirfenidone on markers of
disease progression such as decline in forced vital
capacity (FVC), progression-free survival and distance
walked in a 6-min walk test (6MWT) (36). A Cochrane
meta-analysis on the cumulative data of these trials
involving 1155 patients showed that pirfenidone reduced
the decline of FVC and the risk of disease progression by
30% compared with placebo (7). At week 72, pirfenidone
also reduced the proportion of patients with a decline of
50 m or more in the 6-min walk distance (31% relative
reduction vs. placebo) and reduced the risk of death or
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disease progression (26% reduction vs. placebo) (7).
Patients participating in RCTs represent a highly selected
group of patients fulfilling strict inclusion and exclusion
criteria as shown by the high screen failure of 70% in the
ASCEND study (6). In a real-life setting, patients with
comorbidities such as concomitant emphysema and heart
disease are likely to be included and treated contrary to
the RCTs. Therefore, it is important to evaluate if the
results of evidence-based therapy can be extrapolated to
daily clinical practice.
Nine single-centre studies from Europe and Japan
including between 40 and 128 patients have previously
reported on the use of pirfenidone in a real-life setting.
These studies, similar to RCTs, reported either a stabili-
sation of pulmonary function or a reduction in FVC
decline (819). Treatment discontinuation due to adverse
events ranged from 1 to 19%.
This study describes the nationwide implementation of
pirfenidone treatment for patients with IPF in Denmark.
The objective of this study was to describe the target IPF
population, safety of pirfenidone, adherence to pirfeni-
done treatment and its effect in real-life clinical practice.
Material and methods
The study was a national multicentre study collec-
ting retrospective data from electronic patient records at
the three Danish tertiary ILD centres at Gentofte
University Hospital, Aarhus University Hospital and
Odense University Hospital. All patients with a confident
diagnosis of IPF according to the 2011 ATS/ERS/JRS/
ALAT statement (1) and who had received at least one
dose of pirfenidone between December 2011 and 30
September 2014 were included. Nine patients with a
definite usual interstitial pneumonia (UIP) pattern on
high-resolution computed tomography (HRCT) diag-
nosed before 2011 had a surgical lung biopsy confirming
the diagnosis. The study period was 33 months. Based on
the recommendations of the Danish Society of Respira-
tory Medicine, only patients with mild-to-moderate IPF
were considered eligible for pirfenidone treatment; thus,
most patients fulfilled the inclusion and exclusion criteria
of the CAPACITY trials (3). Initially, patients with
diffusing capacity for carbon monoxide (DLCO) below
35% of predicted were not considered eligible for pirfeni-
done treatment. After the publication of the ASCEND
trial (6) in May 2014, the threshold for eligibility was,
however, changed to DLCO above 30%.
The data collection included baseline demography,
HRCT patterns, histopathology, FVC, FVC percent of
predicted (FVC%), forced expiratory volume in 1 sec
(FEV1), FEV1 percent of predicted (FEV1%), DLCO
percent of predicted (DLCO%) and the 6MWT. In addi-
tion, longitudinal data on lung function, 6MWT, adverse
events, adherence to treatment and vital status were
collected. All patients had baseline liver function tests
and full blood count tests prior to commencing pirfenidone
treatment.
Patients were monitored every 36 months in their
ILD outpatient clinic. All patients had telephone access
to a patient responsible nurse. Treatment-related adverse
events and treatment compliance were recorded at each
visit.
The study protocol was approved by The Danish Data
Protection Agency. The local ethics committees needed
no approval, as the study was retrospective and pirfeni-
done was already approved in Denmark.
Pirfenidone administration
The pirfenidone dose was as a standard escalated over
2 weeks to the full recommended dose of 2,403 mg. In line
with recent expert recommendations, dose adjustment
measures were undertaken in case of side effects
until symptoms resolved (20). Dose adjustment measures
included dose reduction, dose interruption, later re-
challenging and sometimes a slower re-escalation in
accordance with clinical judgment and patient acceptance.
Patient responsible nurse
Dedicated nurses specialised in IPF and caring for and
advising patients in the outpatient setting were available to
the patients in all participating ILD centres by telephone.
The nurses informed the patients and spouses thoroughly
on how to take pirfenidone capsules with food, that the
three capsules can be taken separately during the meal and
that gastrointestinal side effects typically are expected to be
worse in the first 46 weeks of treatment. Patients were also
educated in avoiding unnecessary exposure to sun and in
the proper use of sun screen, and encouraged to avoid
outdoor activities in the middle of the day and in the hours
immediately after ingestion of capsules. The nurses handed
out patient information leaflets and gave advice on other
prophylactic means against possible adverse events and
management strategies to manage any potential adverse
events. Either a visit to the clinic or a telephone consulta-
tion with the nurse was scheduled 23 weeks after starting
pirfenidone treatment. Nurses were allowed to reduce and
re-escalate pirfenidone doses and could also guide patients
in questions regarding long-term oxygen therapy and
ambulatory oxygen therapy. If needed, a pulmonologist
specialised in IPF could be consulted. In the case of acute
admission, the nurse could be contacted to coordinate
follow-up after discharge.
Statistical analysis
For the description of baseline demographics, data are
presented as mean and standard deviation unless otherwise
stated. For the longitudinal analysis, all available data were
included. A random coefficient regression model with
linear time effect was applied. Median survival was
estimated using the KaplanMeier method. The statistical
Goran Nadir Salih et al.
2
(page number not for citation purpose)
Citation: European Clinical Respiratory Journal 2016, 3: 32608 - http://dx.doi.org/10.3402/ecrj.v3.32608
analysis was performed using the SAS statistical software
version 9.2.
Results
Baseline demographics
From 21 December 2011 to 30 September 2014, a total of
113 patients with IPF who had received at least one dose
of pirfenidone were included. Patients were followed for
0.133.8 months (median 9.4 months). The baseline
characteristics of the study cohort are summarised in
Table 1.
Mean age at pirfenidone treatment start was 69.6
(98.1 years), and 71% of the patients were males. The
majority of patients were former smokers (68%). None of
the patients were current smokers. At baseline, the mean
FVC was 80% (917.9) and the mean DLCO was 45.9%
(910.3). Eleven percent of patients were on supplemental
oxygen therapy.
Figure 1 shows the distribution of patients with a
reduced FEV1/FVC ratio indicative of a mixed obstruc-
tive and restrictive decrease in lung function as a function
of FEV1. Fourteen (12%) patients had a FEV1/FVC ratio
below 0.70.
The diagnosis of IPF was based on clinical evalua-
tion, autoantibody screening (anti-nuclear antibody, anti-
neutrophil cytoplasmic antibody, immunoglobulin M
rheumatoid factor and anti-citrullinated peptide anti-
body), various combinations of HRCT and histopatholo-
gical patterns (Table 2). In 64 patients (56.6%), the
diagnosis was based on a definite UIP pattern on HRCT
without a surgical lung biopsy. Nine patients with definite
UIP pattern on HRCT had undergone a surgical lung
biopsy prior to the publication of the current guidelines.
In 36 patients (31.9%) with possible or inconsistent HRCT
patterns, the diagnosis was confirmed by a surgical lung
biopsy and subsequent multidisciplinary conference
(MDC) with the participation of pulmonologists, radi-
ologists and pathologists. In four patients (3.5%) with
possible UIP pattern on HRCT, clinical information
(all four) and bronchoalveolar lavage and transbronchial
biopsy findings (three patients) were evaluated at an MDC
to obtain a final diagnosis of IPF. Bronchoscopy
with bronchoalveolar lavage was performed in 42 patients
(37%) and forceps transbronchial biopsies in 23%
of patients. However, transbronchial biopsies only
contributed to the diagnosis in few patients.
The annual decline in FVC (mean9standard error
of the mean (SEM)) from baseline during 33 months of
follow-up was 164.0933.2 ml (FVC% 3.6%91.0).
The annual decline in DLCO% from baseline was
2.290.8% (mean9SEM). The decline in 6MWT from
baseline was 18.2911.2 m (mean9SEM).
Thirteen patients (11.5%) died during the 33 months
corresponding to an estimated annual all-cause mortality
Table 1. Baseline characteristics of patients treated with
pirfenidone (n113). Figures are mean9SD unless otherwise
stated
Characteristics Value Range
Age (years) 69.698.1 43.082.0
Males, n (%) 80 (71%)
Body mass index 26.894.0 15.637.7
Smoking history%
(current/former/never)
0/68/32
FEV1/FVC 0.8090.08 0.550.95
FVC (L) 2.8490.9 1.245.45
FVC% predicted 80.3917.9 46121
DLCO% predicted 45.9910.3 1870
6MWD (m) 445.7994.1 145640
Oxygen saturation at rest (%) 96.692.1 90100
Desaturation at 6MWT (%) 9.196.5 311
DesaturationB88% at 6MWT (n) 41
DLCO: carbon monoxide diffusing capacity, FEV1: forced
expiratory volume in 1 sec, FVC: forced vital capacity, SD:
standard deviation, 6MWD: 6-min walking distance.
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Fig. 1. The component of airflow obstruction among the
study participants.
Table 2. Diagnosis of IPF
Video-assisted thoracoscopic lung
biopsy
HRCT Number
Not
performed Definite Probable Possible
Definite 73 64 8 1 0
Possible 34 4 20 3 7
Inconsistent 6 0 6 0 0
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rate of 14.7%. The KaplanMeier plot of the group for
all-cause mortality estimate is shown in Fig. 2.
Safety
Eighteen patients (16%) discontinued pirfenidone treat-
ment due to adverse events. Table 3 summarises adverse
events with a frequency of more than 5%. Fifty-one
patients (45.2%) needed dose adjustment to continue
adherence to treatment.
Nausea occurred in 44% of patients and fatigue in
38.9%. Skin-related adverse events, primarily photosensi-
tivity, were common and occurred in 32.7%.
The adverse events were mild to moderate and mostly
tended to occur within the first 810 weeks of treat-
ment. No severe, new or unexpected adverse events were
observed.
Discussion
This study is the first national multicentre study including
all patients with IPF and treated with pirfenidone in a
real-life setting. The main findings are that pirfenidone
treatment in clinical practice is associated with a similar
reduction of FVC decline and the same number of
adverse events as in the intervention groups in existing
RCTs. A careful dose adjustment programme coordi-
nated by physicians and dedicated nurses ensured a high
adherence to pirfenidone treatment.
All patients in this study had mild-to-moderate IPF
reflected by a mean FVC of 80.3% of predicted, a mean
DLCO of 45.9% and a mean 6MWT of 446 m. The mean
age was 69 years, and the majority of patients were
former smokers and males. All patients met most of the
inclusion criteria of the CAPACITY trials and are thus
comparable with the patient cohorts from RCTs. How-
ever, we included more patients with comorbidities such
as emphysema and heart disease as reflected in the
number of included patients (14 patients) with a FEV1/
FVC ratio below 0.70. In spite of this, the annual rate of
decline in FVC was similar to the intervention groups in
the CAPACITY and ASCEND studies (3, 6).
The number of diagnosed and treated patients in
Denmark is far less than the estimated incidence rates,
although regional differences exist. There are a number
of possible explanations for this difference. Firstly, a
guideline-based confident diagnosis of IPF requires a
surgical lung biopsy in patients with a possible UIP
pattern on HRCT. It is well known in clinical practice
that many patients are not referred to surgical lung
biopsy due to procedure risk (comorbidities, high age and
low DLCO) or patient preferences. Secondly, patients with
severe IPF, defined as FVC B50% or DLCO B35% of
predicted, were not considered for treatment until the
results of the ASCEND study were published where the
limit of DLCO was changed to 30%. Thirdly, older
patients and patients with severe comorbidities are often
not prescribed pirfenidone because of a negative risk
benefit relation. Finally, few patients who were eligible for
treatment choose to wait and see without medical
treatment after thorough information.
The nature of adverse events in our study was similar to
that reported in the ASCEND and CAPACITY studies;
neither new, unexpected nor any severe side effects were
observed. The adverse events were tolerable and almost
exclusively mild to moderate in intensity. The most
commonly reported adverse events were gastrointestinal
and skin-related events, mostly photosensitivity. The
frequency of fatigue in our study was higher (38.9%)
than in the CAPACITY (7%) and ASCEND (21%) trials
(3, 6). Patients reported an increased degree of fatigue few
weeks after treatment initiation. A careful clinical evalua-
tion concluded that symptoms of fatigue were drug related
rather than disease related in most patients. A clinically
significant elevation of liver enzymes was experienced in
only one patient (0.9%), and it was reproducible and fully
reversible.
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Fig. 2. The KaplanMeier survival curve with 95% confidence
intervals.
Table 3. Adverse events with a frequency of more than 5%
Adverse events No. Percent
Nausea 50 44.2
Vomiting 12 10.6
Diarrhoea 25 22.1
Dyspepsia 35 31.0
Decreased appetite 45 39.8
Weight loss 26 23.0
Taste disturbance 7 6.2
Cough 25 22.1
Dizziness 14 12.4
Fatigue 44 38.9
Insomnia 13 11.5
Skin-related reactions 37 32.7
Arthralgia/muscle pain 10 8.8
Goran Nadir Salih et al.
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Most of the side effects presented in the first weeks of
treatment and were managed by a careful proactive and a
tailored dose adjustment programme managed by physi-
cians and dedicated nurses thus ensuring a high rate of
adherence. The discontinuation rate was low and similar
to the RCTs despite more patients with more comorbid-
ities were included. The comprehensive and thorough
information given to patients and coordinated by both
doctors and nurses contributed to the high adherence rate
of 84% in our study.
Skin-related events were primarily photosensitivity,
which was resolvable after protective measures were taken.
In the case of allergic rashes or if dose adjustment and
protective measures were unsuccessful in ameliorating the
symptoms, the patients discontinued the treatment.
Nausea was the most frequent gastrointestinal adverse
event, reported by 44% of patients in our study, and a little
higher than in the active arms of the two multicentre RCTs,
where nausea was reported in 36% of cases (3, 6). It was
resolvable in almost all cases with the help of the dose
adjustment measures, anti-acid or anti-peristaltic drugs.
It has been shown in both phase III RCTs and animal
studies that the anti-fibrotic effect of pirfenidone is dose
related and maintaining as high a dose as possible is
therefore important for treatment outcome (37, 21).
The dose adjustment measures and the coordinated
efforts such as patient education and motivation by
both the pulmonologists specialised in IPF and specia-
lised nurses were considered pivotal to the high adherence
to treatment.
The annual decline of FVC and 6MWT in our study was
encouraging. The mean annual decline in percent of
predicted FVC from baseline was 3.691.0% and consider-
ably below the 10% decline regarded as a marker of severe
progression. The same was the case with the annual mean
decline of DLCO by 2.290.8% from the baseline, which
is likewise below the clinically significant threshold of
15% (1).
The mean annual decline in 6MWT was 18.2911.2 m.
The minimum clinically important difference of the
decline in the walk test in patients with IPF has been
reported as 2445 m or more. The longitudinal variation
in the 6MWT has been used to predict the disease status
and progression (22, 23) as well as an outcome measure in
many clinical trials enrolling subjects with IPF (3, 6).
We acknowledge some limitations in drawing any
statistical conclusions from our retrospective observa-
tional real-world study both because of the relatively
short observation period and the lack of an appropriate
control group. To further strengthen our efficacy data, it
would have been ideal if we could compare the rate of
decline of FVC post-treatment to pre-treatment tests.
However, this was impossible as most patients were newly
referred and without previous pulmonary function test
results.
In conclusion, our findings provide further evidence
that pirfenidone treatment of patients with IPF in a real-
life setting is safe and generally well tolerated. Gastro-
intestinal side effects, skin events and fatigue were the
most commonly reported adverse events. Adverse events
were generally mild to moderate in severity and only led
to treatment discontinuation in a minority of patients.
Adverse events tended mostly to occur during the first
3 months of treatment and were almost always resolvable.
The adherence to the treatment was high due to a careful
follow-up and dose adjustment programme. The annual
decline in physiological parameters was comparable to
the active arms of published RCTs.
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